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ORIGINAL ARTICLE
Glomerular crescent formation can be observed
in a variety of glomerulonephritis (GN) and is
not a unique feature of any single disease entity.
Rapidly progressive GN (RPGN) is a syndrome
characterized clinically by an acute deterioration
in renal function, and morphologically by wide-
spread formation of circumferential crescent for-
fmation, generally involving more than 50% o
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Methods: This retrospective study analyzed medical records and pathology slides of patients who received
renal biopsy between February 1998 and October 2004. Enzyme-linked immunosorbent assay was used
routinely for ANCA testing in all patients.
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patients were younger (p = 0.028), while PICGN patients had more chronic lesions (p < 0.001), extensive
glomerular crescents (p < 0.001), less severe proteinuria (p < 0.001) and poorer renal survival (p = 0.0017).
Among the PICGN patients, 62.5% had a positive ANCA test, 80% had myeloperoxidase-ANCA and 20%
had proteinase-3-ANCA. Subgroup analysis showed that ANCA negativity was associated with tless crescen
formation (p < 0.001) but more chronic glomerular lesions (p < 0.001) and a trend toward worse renal out-
come (p = 0.055).
Conclusion: This study illustrates the necessity for pathologic diagnosis of pauci-immune GN despite
ANCA negativity. The poor prognosis associated with ANCA negativity in this study may be partly due 
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glomeruli.1,2 It is a medical emergency with cata-
strophic renal prognosis unless treated aggres-
sively. Even several days’ delay in diagnosis and
treatment can have a major negative impact on
outcome because of the rapidly progressing loss
of renal function that typically accompanies GN
with extensive glomerular crescents, namely cres-
centic GN. This disorder is most commonly due to
one of three different mechanisms of glomerular
injury.3 The first of these, antiglomerular basement
membrane (anti-GBM) GN, is responsible for
10–20% of cases with extensive glomerular cres-
cents. When associated with pulmonary hem-
orrhage, it is known as Goodpasture’s syndrome.
A second mechanistic form is immune complex
GN. This entity, which is responsible for approx-
imately 40% of all cases, can be due to one of a
number of systemic diseases including postinfec-
tious GN, immunoglobulin A (IgA) nephropathy,
lupus nephritis, membranous nephropathy and
membranoproliferative GN (MPGN). The third
mechanistic form is pauci-immune GN, in which
glomerular inflammation and necrosis are present
with few or no immune deposits. A large majority
of patients with this disorder have systemic vas-
culitis, including Wegener’s granulomatosis, micro-
scopic polyangiitis and Churg-Strauss syndrome.4
Neutrophil dysfunction plays a major role in the
pathogenesis of medium and small vessel vasculi-
tis, a concept reinforced by the demonstration of
the antineutrophil cytoplasmic antibody (ANCA)
in 1985.5,6 ANCA assays are now in routine clinical
use and directed against several myeloid enzymes,
of which ANCA to proteinase-3 (PR3-ANCA)
and myeloperoxidase (MPO-ANCA) are the
most common.7
However, ANCAs were only detected in 
75–90% of patients with pauci-immune GN, and
in a significant number of these patients, ANCAs
were absent despite repeated testing.8 ANCA-
positive pauci-immune GN patients had different
clinical presentations compared with ANCA-
negative pauci-immune GN patients.9 Our previ-
ous study found a protracted course of leukocytosis
and upper airway involvement in some patients
with ANCA-positive pauci-immune GN,10 whereas
such a clinical course was not observed in ANCA-
negative patients.9 The purpose of this study was to
compare the clinical presentation, renal morphol-
ogy and clinical outcomes among ANCA-positive
pauci-immune GN, ANCA-negative pauci-immune
GN and other GNs with crescent formation (espe-
cially lupus nephritis).
Methods
Patients
In total, 759 biopsies were performed on the native
ykidneys of patients in National Taiwan Universit
rHospital between February 1998 and Octobe
t2004. All kidney tissues were examined by ligh
microscopy (LM), immunofluorescence micro-
scopy (IF) and/or electron microscopy (EM). The
rdate of renal biopsy was used as the start date fo
entry into the study. The end point for renal sur-
vival analysis was the start of long-term renal re-
placement therapy or death due to renal failure.
Indications for renal biopsy
Acute renal failure (ARF) or rapidly progressive
renal failure (RPRF) was the indication for renal
biopsy if the patient’s serum creatinine level dou-
 bled or increased more than 1 mg/dL in a period
of less than 3 months. Chronic renal failure (CRF)
was defined as less than 1mg/dL elevation of serum
creatinine levels during a period of more than 3
months. Proteinuria was defined as the pres fence o
0.5 g or more of protein in 24-hour urinary sam-
ples. Non-nephrotic proteinuria was defined as
proteinuria without edema and hypoalbumine-
mia. Nephrotic range proteinuria was defined as
daily proteinuria more than 3 g. Hematuria was
defined as the presence of five or more red blood
t cells per high power field in urinary sedimen
examination.
Renal pathology
Renal pathology study was performed as described
previously.10 The extent of glomerular damage was
evaluated by examining glomeruli in each patient,
and expressed as the percentage of glomeruli with
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necrosis, cellular crescents, fibrocellular crescents,
fibrous crescents and global sclerosis. The extent
of tubular damage was expressed as the percentage
of tubular sections with atrophy. Interstitial fibro-
sis was graded semiquantitatively on a scale of
0–3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
Acute glomerular lesions consisted of cellular and
fibrocellular crescents, and chronic glomerular
lesions consisted of fibrous crescents and global
sclerosis. Immunoglobulins (IgG, IgA, IgM), com-
plement (C3, C1q) and properdin were scored
on their granular or linear aspect, intensity (on a
scale of 0 to 4+, with 0 being least intense and 4+
being most intense), and their site (mesangial,
peripheral, or outside the glomerular tufts, includ-
ing crescents and/or necrosis). Deposits in arteries,
arterioles and the tubular basement membrane
were also scored. Diagnoses were established based
on the findings of LM, IF and EM, together with
clinical features and results of appropriate sero-
logic tests such as antinuclear antibody, antistrep-
tolysin O antibody and anti-GBM antibodies, and
ANCA. A paucity of immune deposits was defined
as less than 2+ immunoglobulin deposits under
IF. Renal pathology in patients with lupus nephri-
tis was classified according to the World Health
Organization classification system.11
Miscellaneous measurements
Serum creatinine and urinary protein were meas-
ured using the enzymatic method and sulfosalicylic
facid method, respectively, of the Department o
yLaboratory Medicine, National Taiwan Universit
Hospital. ANCA was tested as described previ-
ously.10 All sera were collected during diagnostic ex-
aminations prior to immunosuppressive therapy.
Statistical analysis
Statistical analyses were performed using SPSS
(SPSS Inc., Chicago, IL, USA) for Windows. Data
were analyzed using the t or χ2 test depending on
rthe nature of the variables. The Kaplan–Meie
method was performed to estimate kidney sur-
gvival, using the study entry date as the startin
date of the survival curve. When death occurred
within 3 months after treatment initiation, with-
out recovery of renal function, the patient was
censored from the kidney survival analysis. Other-
wise, subject withdrawal or loss to follow-up was
censored. Differences between survival curves were
tested with the log-rank test. The level of signifi-
cance was set at 0.05.
Results
Clinical diagnosis and renal outcome of
crescentic GN
GN was diagnosed in 637 of the 759 patients in
whom renal biopsies were performed for various
indications. Glomerular crescent formation was
found in 88 of t these patients (Table 1). The mos
Table 1. Indications for renal biopsy and prevalence of glomerular crescents
Indication for renal biopsy Patients, n (%)
Patients with glomerular
crescents, n (%)
Nephrotic syndrome 362 (47.7) 12 (13.6)
ARF/RPRF 165 (21.7) 70 (79.5)
Non-nephrotic proteinuria 89 (11.7) 1 (1.1)
Non-nephrotic proteinuria and hematuria 60 (7.9) 1 (1.1)
CRF 46 (6.1) 4 (4.5)
Asymptomatic hematuria 34 (4.5) 0 (0)
Other* 3 (0.4) 0 (0)
Total 759 (100) 88 (100)
*Other indications were Bartter’s syndrome (two patients) and Gitelman’s syndrome (one patient). ARF = acute renal failure; RPRF =
rapidly progressive renal failure; CRF = chronic renal failure.
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frequent indications for renal biopsy were
nephrotic syndrome (47.7% of all patients),
ARF/RPRF (21.7%) and non-nephrotic protein-
uria (11.7%). Glomerular crescents were highly
prevalent in patients with ARF/RPRF (42.4%),
which accounted for 79.5% of the 88 biopsies
with glomerular crescents. Twelve patients with
glomerular crescents had nephrotic syndrome
caused by lupus nephritis (n = 10) and MPGN
(n = 2). Glomerular crescents were rare in patients
with non-nephrotic proteinuria and/or hematuria,
with the exception of one patient with pauci-
immune GN and one with lupus nephritis.
In the 88 biopsies with glomerular crescents,
five categories of renal pathology were identi-
fied. However, definite diagnoses could not be
made in five patients because of extensive fibro-
sis (Table 2). Pauci-immune GN (n = 42) was the
commonest diagnosis of renal pathology with
glomerular crescents, accounting for nearly 50%
of cases. Moreover, half of patients with pauci-
immune GN had glomerular crescents in more
than 50% of examined glomeruli, i.e. pauci-
immune crescentic GN (PICGN). Lupus nephritis
(n = 25) was the second most common diagnosis
of renal pathology, accounting for 28.4% of cases
with glomerular crescents. Of the 25 patients with
lupus nephritis, only two had glomerular crescents
in more than 50% of examined glomeruli. MPGN
and poststreptococcal GN (PSGN) were not com-
mon; however, about one-third of patients with
these pathologies had glomerular crescents. Cres-
cents were not found in patients with membra-
rnous nephropathy, minimal change disease o
focal segmental glomerulosclerosis.
The mean follow-up period was 18.6 months.
rRenal survival of GN patients with glomerula
crescents was poorer than that of GN patients
without glomerular crescents (Figure 1). Progres-
sion to end-stage renal disease (ESRD) occurred
in 43 patients, accounting for 48.9% of patients
with glomerular crescents (Table 2). Multivariate
analysis showed that development of ESRD was
associated with more extensive glomerular cres-
cents (p < 0.001) and chronic glomerular lesions
Table 2. Characteristics of glomerular crescent formation according to renal pathology
Patients with Percentage of Patients with
Renal pathology Patients, n glomerular glomeruli with glomerular crescents ESRD, n
crescents, n (%) crescents* >50%, n (%)
IgA nephropathy 75 7 (8) 42.3 ± 21.0 1 (4) 5
Lupus nephritis 60 25 (28.4) 24.0 ± 16.1 2 (8) 6
Pauci-immune GN 42 42 (47.7) 48.7 ± 25.2 21 (84) 27
MPGN 26 7 (8) 22.0 ± 19.4 1 (4) 2
PSGN 6 2 (2.3) 29.0 ± 0.6 0 (0) 0
Unclassified GN 5 5 (5.7) 20.2 ± 13.8 0 (0) 3
Total 88 (100) 25 (100)
*Continuous data are expressed as mean± standard deviation. ESRD = end-stage renal disease; IgA = immunoglobulin A; GN = glomeru-
lonephritis; MPGN = membranoproliferative glomerulonephritis; PSGN = poststreptococcal glomerulonephritis.
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(p=0.002) compared to other more favorable renal
outcomes. Patients with and without glomerular
crescents did not differ in baseline variables in-
cluding age, gender, proteinuria, tubular atrophy,
interstitial fibrosis and acute glomerular lesions.
Although only 8% of patients with IgA
nephropathy had glomerular crescents, the cres-
cent formation in these patients was extensive
(42.3 ± 21.0% of glomeruli). Notably, renal sur-
vival was poorest in IgA nephropathy patients with
glomerular crescents, 71.4% of whom developed
ESRD during the follow-up period. In addition to
the extensive crescent formation, extensive inter-
stitial fibrosis (2.0 ± 0.8) and tubular atrophy
(31.1 ± 23.4%) were also noted. Due to the small
case numbers of IgA nephropathy, MPGN, acute
PSGN and unclassified GN, the analysis was
focused on the clinicopathologic characteristics
of patients with pauci-immune GN or lupus
nephritis.
Comparison of lupus nephritis and
pauci-immune GN
Age and gender were significantly different be-
tween the lupus nephritis and pauci-immune
groups, with the lupus nephritis group having
younger and more female patients (Table 3).
Lupus nephritis patients with glomerular crescents
mainly had class IV disease (24 patients), which
is known to be correlated with the highest lupus
activity and worst prognosis. Patients with pauci-
immune GN had extensive glomerular crescents
with more chronicity and tubular atrophy. A sig-
nificantly higher percentage of patients with
pauci-immune GN presented with RPRF clini-
cally. Renal survival was much poorer in patients
with pauci-immune GN with glomerular crescents
Table 3. Comparison of the clinical features and renal pathology between patients with pauci-immune
glomerulonephritis (GN) and lupus nephritis*
Pauci-immune Lupus-nephritis
p†
GN (n = 42) (n = 25)
Age (yr) 54.7 ± 17.4 33.6 ± 13.1 0.028
Gender (M/F) 23/19 6/19 < 0.001
RPRF (n) 33 10 0.001
Serum creatinine (mg/dL) 5.6 ± 3.0 2.6 ± 2.1 0.094
Proteinuria (g/d) 2.9 ± 1.9 6.9 ± 5.4 < 0.001
Dialysis needed at presentation (n) 13 5 0.328
Percentage of glomeruli with crescents 48.7 ± 25.2 24.0 ± 16.1 0.016
> 50% of glomeruli with crescents (n) 21 2 < 0.001
Acute glomerular lesions (%) 28.1 ± 22.7 21.6 ± 17.5 0.092
Chronic glomerular lesions (%) 53.4 ± 29.0 2.5 ± 4.8 < 0.001
Interstitial fibrosis 2.0 ± 0.7 1.1 ± 0.6 0.375
Tubular atrophy (%) 31.7 ± 18.3 11.4 ± 10.5 0.001
*Continuous data are expressed as mean ± standard deviation; †continuous data were compared using the t test, and dichotomous and
polychotomous data were compared using the χ2 test. RPRF = rapidly progressive renal failure.
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compared to that of patients with lupus nephritis
(p = 0.0017; Figure 2).
Subgroup analysis of pauci-immune GN
We further analyzed the clinical features and renal
pathology of the pauci-immune GN group. ANCA
serologic results were available for 40 of these pa-
tients, of whom 25 (62.5%) were ANCA-positive
(Table 4). Seventy-six percent of ANCA-positive
patients were MPO-positive, 20% were PR3-
positive and the remaining 4% were positive for
both. About half of the patients with pauci-
immune GN presented with pulmonary–renal
syndrome that consisted of nephritis, hemoptysis
and/or radiologic evidence of pulmonary in-
volvement (Table 4). Notably, systemic involve-
fment was more common in the subgroup o
ANCA-positive patients (72%) (p=0.005; Table 5).
Moreover, ANCA-positive patients were older (p=
0.008), and had more acute glomerular lesions
(p < 0.001) and crescent formation (p = 0.003) in
examined glomeruli. Although RPRF was a more
common presentation in ANCA-negative pa-
tients (p = 0.014), their glomerular lesions were
more chronic at the time of diagnosis (p < 0.001).
rAccordingly, renal survival was marginally bette
Table 4. Results of antineutrophil cytoplasmic antibody (ANCA) tests in patients with pauci-immune
glomerulonephritis (GN)
ANCA Total patients, n
Patients with pulmonary– Patients with renal-
renal syndrome, n limited GN, n
MPO-positive 19 13 6
PR3-positive 5 4 1
MPO- + PR3-positive 1 1 0
Negative result 15 4 11
Unknown* 2 0 2
Total 42 22 20
*Unknown means ANCA test results were not available. MPO = myeloperoxidase; PR3 = proteinase-3.
Table 5. Comparison of the clinical features and renal pathology between antineutrophil cytoplasmic antibody
(ANCA)-positive and ANCA-negative patients with pauci-immune glomerulonephritis (GN)*
ANCA(+) (n = 25) ANCA(−) (n = 15) p†
Age (yr) 59.1 ± 17.6 45.1 ± 13.5 0.008
Gender (M/F) 14/11 8/7 0.870
RPRF (n) 17 15 0.014
Serum creatinine (mg/dL) 5.7 ± 3.5 5.5 ± 2.3 0.254
Proteinuria (g/d) 2.9 ± 2.0 3.1 ± 1.9 0.320
Dialysis needed at presentation (n) 9 4 0.542
Renal-limited GN (n) 7 11 0.005
Systemic vasculitis‡ (n) 18 4 0.005
Percentage of glomeruli with crescents 57.3 ± 25.1 34.2 ± 19.8 0.003
> 50% of glomeruli with crescents (n) 15 5 0.102
Acute glomerular lesions (%) 30.8 ± 22.5 24.7 ± 23.4 < 0.001
Chronic glomerular lesions (%) 44.5 ± 29.6 62.1 ± 27.4 < 0.001
Interstitial fibrosis 2.1 ± 0.8 1.9 ± 0.6 0.159
Tubular atrophy (%) 28.0 ± 16.5 36.7 ± 19.9 0.293
*Continuous data are expressed as mean ± standard deviation; †continuous data were compared using the t test, and dichotomous
and polychotomous data were compared using the χ2 test; ‡systemic vasculitis = Wegener’s granulomatosis or microscopic polyangiitis.
RPRF = rapidly progressive renal failure.
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in ANCA-positive patients than in ANCA-negative
patients (p = 0.0555; Figure 3).
Discussion
This investigation of 88 kidney disease patients
with glomerular crescents confirmed that the long-
term prognosis of this disease is generally unfa-
vorable, although prognosis may vary widely in
any given case. The approach of categorization
based on the pathogenic mechanism has contri-
buted greatly to the diagnosis and management
of patients. Our review of the literature found 
no previous reports of studies comparing renal
pathology and outcome in patients with serologic
ANCA-positive and -negative pauci-immune GN
in Asian populations. Limitations of this study
include its retrospective design, performance of
ANCA assay only by enzyme-linked immunosor-
bent assay and the use of routine clinical notes
for data collection.
None of the patients in this study had biopsy-
proven anti-GBM GN, a condition responsible for
10–20% of all patients with RPGN in Western
studies, but extremely rare in the Asian popula-
tion.2 In this study, biopsies showed crescent for-
mation in 100% of patients with pauci-immune
GN, and 48.7 ± 25.2% of glomeruli had crescents
xin these patients. In contrast, immune-comple
GN, such as lupus nephritis, MPGN, IgA nephro-
fpathy and PSGN, had a much lower frequency o
crescent formation. These findings are compati-
yble with a study series from the United States b
Jennette.12
A previous study found that biopsy with a
high chronicity and a low activity index predicted
a higher renal fatality outcome despite vigorous
immunosuppressive therapy in pauci-immune GN
patients.13 Age and serum creatinine level also
tsignificantly predicted renal survival. Although i
is difficult to determine cut-off values for age,
ypretreatment renal function loss and renal biops
findings to decide whether or not to treat a patient,
several suggestions may be inferred.10,14 yIt ma
be reasonable to withhold immunosuppressive
treatment in patients with ANCA-negative pauci-
immune GN and one of the following fea-
tures: age > 70 years; indolent renal function loss
(doubling of serum creatinine in more than 3
months); and/or a high chronicity index on
rrenal biopsy (percentage of chronic glomerula
lesions > 30%). In these instances, a short course
of steroids may still be considered. In contrast,
involvement of other organs, e.g. pulmonary in-
volvement or scleritis, still necessitates aggressive
immunosuppressive therapy even when such a
therapy is no longer warranted for renal function
preservation.
On multivariate analysis, sepsis was found to
be a major predictor of patient survival.10 This
finding illustrates the need for early diagnosis
and referral. When patients were referred late,
more aggressive immunosuppression was used
and the severity of the underlying vasculitic process
may have resulted in more septic complications.10
Although all the patients in the present study were
treated rwith immunosuppressive therapy, thei
regimens were not standardized and, therefore,
an analysis of the effect of therapy on renal out-
ccome in combination with the histopathologi
data was not performed.
In this study, there are three potential expla-
nations for ANCA negativity in pauci-immune
GN patients. First, these patients may have had
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iF gure 3. f l lComparison o  rena  surviva  in ANCA-positive
(n = 25; solid line) and ANCA-negative (n = 15; dashed line)
patients with pauci-immune glomerulonephritis using the
Kaplan–Meier method (p = 0.0555).
other etiologic agents that produced the same
final common pathway of glomerular vascular 
injury (e.g. ANCA with specificities that are not
detected by current assays).12 Second, our ANCA-
negative cases may not have had enough time
prior to diagnosis to develop ANCA. Third, they
may have had false negative results.9 In our 
study, these cases had less systemic involvement,
more clinical RPRF instead of ARF and more
chronic glomerular lesions on renal biopsy. In
addition, they demonstrated a borderline signifi-
cantly poorer renal survival rate compared with
ANCA-positive patients (p = 0.0555). Lack of sys-
temic symptoms and ANCA negativity probably
resulted in delayed diagnosis and poorer progno-
sis in these patients. This study also showed that
patients with ANCA-negative pauci-immune GN
were significantly younger, an observation that
has received little attention earlier. Although the
reason for this age difference is unclear, our re-
sults suggest that younger age may be a risk factor
for progression to ESRD in pauci-immune GN.
Crescent formation was found in 41.7% of our
cohort of patients with lupus nephritis. Among
them, 24% developed ESRD with a median 
follow-up of 10 months (range, 2–48 months),
and 24.0 ± 16.1% of glomeruli had crescents.
Extensive crescent formation was infrequently
seen in our patients with lupus nephritis, a find-
ing compatible with the studies of Cameron 
et al,15 McCluskey16 and Ponticelli et al.17
The renal prognosis in patients with IgA neph-
ropathy with crescent formation in this series
was poor, with 71.4% of patients developing ESRD
with a median follow-up of 6 months (range,
1–22 months), and 42.3 ± 21.0% of glomeruli
showing crescents. Tumlin et al18 retrospectively
analyzed a series of 12 patients with IgA nephro-
pathy with at least 10% crescents or endocapillary
proliferation and found that, if untreated, the
ESRD rate was 40% within 3 years. Studies em-
ploying different scoring systems have identified
extensive crescents (>30%), mesangial hypercellu-
larity, global or segmental glomerulosclerosis, seg-
mental necrotizing lesions, interstitial fibrosis, and
vascular lesions as markers of poor prognosis.19–21
r The high prevalence of these features in ou
patients may partly explain their poor renal
prognosis.
In conclusion, our results indicate that pauci-
immune GN is the most common kidney disease
associated with glomerular crescents. Half of the
patients with pauci-immune GN in this series
fulfilled the criteria for crescentic GN. Evaluation
gof renal histopathology is helpful in predictin
renal outcome. ANCA negativity is not uncom-
mon in patients with pauci-immune GN and
may be associated with poorer prognosis due to
delayed diagnosis. Timely renal biopsy should
Abe performed in these patients despite ANC
negativity. Patient age should be considered and
proper evaluation of renal biopsy should be done
when deciding whether or not potentially dan-
gerous immunosuppressive treatment is appro-
priate in pauci-immune GN patients. Finally,
further prospective studies are needed in order to
gain a clearer understanding of the etiology, clin-
ical, serologic and histologic correlations and
outcome of these conditions.
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